Netherlands· NL-727ee9db8fbc

Etcamah 75 mg filmomhulde tabletten

A camizestrant product containing camizestrant + cellulose, microkristallijn (e 460(i)), registered in Netherlands by AstraZeneca AB. The same ATC class is registered in 6 of our 19 countries.

ATC L02BA05

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about camizestrant + cellulose, microkristallijn (e 460(i))Answers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Camizestrant is registered in 6 of 19 countries.

Countries holding a registration under ATC L02BA05 (camizestrant), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
4 of them publish a price we can compare per daily dose

Search camizestrant products by name

Camizestrant · ATC L02BA05

6 / 19 countries

Belgiumprice
Czechiaprice
Denmark
Finlandprice
Netherlands
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)

Active substance: CAMIZESTRANT + CELLULOSE, MICROKRISTALLIJN (E 460(i))
Manufacturer: AstraZeneca AB
Country: Netherlands (NL)
ATC code: L02BA05
ATC class: Camizestrant
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/26/2046

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same class

Other records under L02BA05

Camizestrant, as other registers publish it.

All camizestrant products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/bb284289-2311-4d6a-83fb-e0f0c608e489
GET /v1/drugs/bb284289-2311-4d6a-83fb-e0f0c608e489?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/etcamah-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Camizestrant",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp135386",
  "excipients": [
    "CALCIUMWATERSTOFFOSFAAT 0-WATER (E 341)",
    "IJZEROXIDE GEEL (E 172)",
    "IJZEROXIDE ROOD  (E 172)",
    "IJZEROXIDE ZWART (E 172)",
    "MACROGOL 3350",
    "MAGNESIUMSTEARAAT (E 470b)",
    "NATRIUMZETMEELGLYCOLAAT",
    "POLYVINYLALCOHOL, GEDEELTELIJK GEHYDROLYSEERD (E1203)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "CAMIZESTRANT",
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))"
  ],
  "leaflet_url": null,
  "authorised_at": "2026/07/20",
  "procedure_number": "EMEA/H/C/006494",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/26/2046",
  "additional_monitoring": "Y"
}

API reference MCP server Plans

See everything about camizestrant.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console